Mendus: Immune signals across AML and CML; Q326 results - Edison
Mendus’s Q326 results reflect continued execution of its expanded vididencel strategy across acute myeloid leukaemia (AML) and chronic myeloid leukaemia (CML), supported by initial immunological data from both indications.
ANNONS
In the Phase IIb CADENCE trial, early samples suggest improved immune competence with vididencel, consistent with prior clinical findings. In CML, VITAL-CML cleared its eight-patient safety test and showed encouraging immune-marker trends, although sustained molecular responses have yet to emerge.
Mendus also initiated the Phase Ib DIVA trial in September, broadening its AML programme to patients receiving less-intensive venetoclax plus azacitidine (Ven-Aza). The Q326 operating loss was SEK20.9m (Q325: SEK20.4m), while operating cash outflow eased to SEK18.8m (Q325: SEK20.5m).
Gross cash stood at SEK55.7m at end-Q326, incorporating the SEK16.5m Fenja Capital drawdown. Management reiterates a cash runway into Q227, with additional capital required thereafter. Attention now turns to key CADENCE and DIVA readouts, and further CML data, throughout 2027.